GIC-Backed Chinese Biopharma Firm CStone Raises $284M In HK IPO

CStone Pharmaceuticals, a Chinese clinical-stage biopharmaceutical company, has raised about HK$2.23 billion (US$284.09 million) in an initial public offering on the Hong Kong stock exchange on Tuesday, which makes it become the sixth pre-profit Chinese biotech company to float shares in the financial hub.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in